Stay updated with breaking news from John Mckearn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Dr. Eric Gulve has announced his retirement from BioSTL after 15 years as President of its startup arm, BioGenerator, and as Executive Vice...
Published: Jul 15, 2021 By Kate Goodwin The NK program has taken off with multiple indications. According to Dan Kemp, its lead product, WU-NK-101, is already proving itself in an ongoing Phase I/II trial, demonstrating an "impressive complete response rate in relapsed/refractory AML." It's the promising results of these memory NK cells driving Company founder John McKearn told BioSpace in January that Wugen "started as a twinkle in his eye" to bring a durable, allogeneic CAR-T therapy on the market. At that time, the biotech's natural killer (NK) cell program was a recent additi...
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO April 07, 2021 08:00 ET | Source: Arch Oncology Arch Oncology Brisbane, California, UNITED STATES BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experien...
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO News Provided By Share This Article /EIN News/ -- BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member. “On behalf of th...
/PRNewswire/ -- Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an...